Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.53 |
| ▸ | MEN1 | O00255 | 6/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | MITF | O75030 | 1/20 | 0.51 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.47 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | CRHBP | P24387 | 1/20 | 0.46 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13802487 | 0.87 | MITF (0.67) | MAPTKMT2AMEN1GAARAB9A | |
| SCHEMBL4209269 | 0.87 | MAPT (0.70) | MAPTKMT2AMEN1GAARAB9A | |
| SCHEMBL13802481 | 0.87 | MAPT (0.53) | MAPTKMT2AMEN1GAARAB9A | |
| SCHEMBL13802482 | 0.86 | MAPT (0.52) | MAPTKMT2AMEN1GAARAB9A | |
| SCHEMBL13802476 | 0.79 | PIN1 (0.49) | MAPTKMT2AMEN1GAARAB9A | |
| SCHEMBL17434413 | 0.78 | ALDH1A1 (0.54) | MAPTKMT2AMEN1GAARAB9A | |
| SCHEMBL4211539 | 0.78 | MAPT (0.72) | MAPTKMT2AMEN1GAARAB9A | |
| SCHEMBL4825507 | 0.74 | P2RX1 (0.51) | MAPTKMT2AMEN1RAB9ANPC1 | |
| SCHEMBL6160631 | 0.74 | MAPT (0.72) | MAPTKMT2AMEN1LMNAATM | |
| SCHEMBL4208059 | 0.74 | MAPT (0.70) | MAPTKMT2AMEN1GAARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| WO-2005092062-A2 | COMPOUNDS FOR NEURODEGENERATIVE DISORDERS | MYRIAD GENETICS, INC. (US) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | APP, PSEN2, PSEN1 | MAPT 6/4885KMT2A 2408/4885MEN1 694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.